Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sunitinib + FOLFIRI
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sunitinib + FOLFIRI is an investigational combination therapy used in clinical trials for the treatment of metastatic colorectal cancer (mCRC). Sunitinib is a small molecule multi-targeted tyrosine kinase inhibitor that blocks several receptors involved in tumor angiogenesis and proliferation, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), KIT, FLT3, RET, and CSF1R. By inhibiting these kinases, sunitinib disrupts tumor blood supply and cell signaling pathways essential for cancer growth. FOLFIRI is a standard chemotherapy regimen composed of three drugs: folinic acid (leucovorin), which enhances the efficacy of fluorouracil; fluorouracil (5-FU), an antimetabolite that inhibits DNA synthesis; and irinotecan, a topoisomerase I inhibitor that prevents DNA replication. The combination aims to leverage both targeted antiangiogenic effects from sunitinib with cytotoxic effects from chemotherapy to improve outcomes in mCRC patients[1][2][3][4].
- Other names
- sunitinib malate + FOLFIRIsunitinib + folinic acid, fluorouracil, and irinotecan
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sunitinib + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sunitinib + FOLFIRI.